Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

Symptoms are typically temporary and go away after stopping the drug or having your dosage lowered. Tell your doctor right away if you notice unusual body movements while taking Ingrezza.

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed ... change or lower the dose of antipsychotic medication, potentially jeopardizing patients’ psychiatric ...